GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Cyclophosphamide Drug Interaction Study In Cancer Patients
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Drug: Oral GW679769Drug: IV Cyclophosphamide 500-700mg/m2
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00334646
- Locations
- 🇸🇪
GSK Investigational Site, Lund, Sweden
Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 484
- Registration Number
- NCT00334607
- Locations
- 🇺🇸
GSK Investigational Site, Marshfield, Wisconsin, United States
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 435
- Registration Number
- NCT00334282
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
- Conditions
- Infections, Streptococcal
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1572
- Registration Number
- NCT00334334
- Locations
- 🇪🇸
GSK Investigational Site, Vélez-Málaga / Málaga, Spain
AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT00333723
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
- Conditions
- Postoperative Nausea and VomitingNausea and Vomiting, Postoperative
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 515
- Registration Number
- NCT00334152
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.
- Conditions
- Infections, Streptococcal
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT00333450
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients
- Conditions
- Venous Thromboembolism
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 127
- Registration Number
- NCT00333021
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib
- Conditions
- Whole Cell PertussisTetanusDiphtheriaHepatitis BHaemophilus Influenzae Type b
- Interventions
- Biological: Tritanrix™-HepB/Hiberix™Biological: DTPw-HBV/Hib Kft vaccine GSK323527A
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 148
- Registration Number
- NCT00332566
- Locations
- 🇳🇮
GSK Investigational Site, Leon, Nicaragua
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT00332046
- Locations
- 🇺🇸
GSK Investigational Site, La Jolla, California, United States